Alan H. Bryce, MD

City of Hope

Phoenix, Arizona

Alan H. Bryce, MD, is a medical oncologist and chief clinical officer at City of Hope in Phoenix, Arizona. Dr. Bryce holds an appointment as a professor with the Department of Medical Oncology & Therapeutics Research, with City of Hope, as well as an appointment as a professor of Molecular Medicine at Translational Genomics Research Institute (TGen), which is also part of City of Hope.

Prior to joining City of Hope, Dr. Bryce spent 12 years at the Mayo Clinic in Phoenix, where he served as chair of the Division of Hematology and Medical Oncology, as well as Director of the Mayo Clinic Arizona Comprehensive Cancer Center. Dr. Bryce received his medical degree from the Chicago Medical School, and then completed an internal medicine residency and a hematology and oncology fellowship at the Mayo Clinic in Rochester, Minnesota. During his time at Mayo, Dr. Bryce served as an international co-principal investigator on multiple clinical trials for prostate cancer, with his research focused on cancer genetics, novel therapies and immunotherapeutic approaches.

Talks by Alan H. Bryce, MD

Point-Counterpoint: There is a Role for Currently Available Biomarkers/Genomics in the Risk Stratification of Prostate Cancer

Posted by Alan H. Bryce, MD | May 2020

E. David Crawford, MD, Editor-in-Chief of Grand Rounds in Urology, and Alan H. Bryce, MD, Chair of the Division of Hematology and Medical Oncology and Assistant Professor of Medicine at the Mayo Clinic in Phoenix, Arizona, present a Point-Counterpoint on the relative value of genomics and biomarkers in prostate cancer risk stratification. Dr. Crawford, presenting the pro side, argues that doctors need to do biomarker testing to know which patients to biopsy, follow closely, and treat with radiation. Dr. Bryce, presenting the con side, contends that while germline testing is beneficial, other biomarker tests have inconsistent results for prostate cancer patients.

Adjuvant Therapy in High Risk Renal Cell Carcinoma

Posted by Alan H. Bryce, MD | May 2019

Alan H. Bryce, MD, surveys data from three phase III trials on adjuvant therapies for high-risk renal cell carcinoma. He discusses the controversies following the conclusions of the completed trials and emphasizes the need for research in further adjuvant therapies beyond those that target the VEGF pathway.

Biomarkers in Localized Prostate Cancer: Sure You Can, But Why Would You?

Posted by Alan H. Bryce, MD | Feb 2019

Alan H. Bryce, MD, discusses the role of biomarkers in clinical decision-making for localized prostate cancer. He argues that while currently available assays have demonstrated predictive ability, prospective data remains insufficient to determine whether or not they improve clinically meaningful endpoints.

Genetic Testing and Next Generation DNA Sequencing

Posted by Alan H. Bryce, MD | Feb 2019

Alan H. Bryce, MD, explains the concept of synthetic lethality in the context of BRCA-deficient tumors, as well as resistance to poly (ADP-ribose) polymerase (PARP) inhibition. He also discusses the under-utilization of inherited cancer risk syndromes in prostate cancer practice, research, and guidelines, as well as new pathways for therapeutic targeting

Novel Hormonal Therapies for Prostate Cancer

Posted by Alan H. Bryce, MD | Feb 2018

Dr. Alan H. Bryce, MD, discusses the newest advances and research in prostate cancer treatments that target androgen receptors, such as BET inhibitors and CYP17 inhibitors, as opposed to chemotherapeutic and radiopharmaceutical approaches.